ZJ
中基長壽科學
ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited
中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference is made to the annual report of Zhong Ji Longevity Science Group Limited (the "**Company**") for the year ended 31 December 2024 (the "**2024 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report. This announcement provides supplemental information to the 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.

The Company would like to supplement the following additional information with respect to the section head "USE OF NET PROCEEDS FROM THE SUBSCRIPTION", "SHARE OPTIONS" and "SHARE AWARD SCHEME" disclosed in the 2024 Annual Report.

USE OF NET PROCEEDS FROM THE SUBSCRIPTION

As disclosed in the 2024 Annual Report, the net proceeds (after deducting the relevant costs and expenses) were approximately HK$19.4 million (the "**Net Proceeds**"). The Company applied the Net Proceeds from the Subscription as to 60.0% thereof for the expansion of the existing longevity science business and the new biomedical products trading business. The remaining 40.0% of the net proceeds was allocated for general working capital for payment of staff costs, rental expenses and legal and professional expenses. As at the date of the 2024 Annual Report, the abovementioned net proceeds has been fully utilised as intended.

In addition to the information disclosed in the section headed "USE OF NET PROCEEDS FROM THE SUBSCRIPTION" in the 2024 Annual Report, the Board would like to provide additional information pursuant to paragraph 11(8)(a) of Appendix D2, in particular, in relation to the use of Net Proceeds during FY2024, as follows:

	Percentage	Allocated use of proceeds *HK$'000*	Utilised amount during the year ended 31 December 2024 *HK$'000*	Unutilised balance as of 31 December 2024 *HK$'000*
Expansion of the existing longevity science business and the new biomedical products trading business	60%	11,640	11,640	—
General working capital for payment of staff costs, rental expenses and legal and professional expenses	40%	7,760	7,760	—
		19,400	19,400	—

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide to the shareholders and potential investors of the Company with the following additional information in relation to all share schemes pursuant to the Rule 17.07 and 17.09 of the Listing Rules.

SHARE OPTIONS

2022 Share Option Scheme

No share option was granted under the 2022 Share Option Scheme during FY2024.

The vesting period of options granted under 2022 Share Option Scheme

Unless the Directors otherwise determined and stated in the offer to the participant, there is no minimum period for which an option granted under the 2022 Share Option Scheme must be held before it can be exercised.

SHARE AWARD SCHEME

No restricted shares have been granted under the Share Award Scheme since the adoption of this scheme and up to the date of the 2024 Annual Report.

The total number of shares available for grant under the Share Award Scheme and the 2022 Share Option Scheme at the beginning of the reporting period (i.e. 1 January 2024) and at the end of the reporting period (i.e. 31 December 2024) were 38,701,026 Shares as adjusted taking into account the effect of the Share Consolidation).

CLARIFICATION OF THE ANNUAL REPORT

The Company wishes to clarify that the number of Shares that may be issued in respect of options and awards granted under all share schemes of the Company during FY2024 was "nil" instead of "16.02%" as disclosed in under Directors' Report on page 52 of the 2024 Annual Report.

As no options and restricted shares granted under all its share schemes during the reporting period. As such, the number of Shares that may be issued in respect of options and awards granted during FY2024 was nil.

The Board confirmed that the above supplemental information does not affect any other information contained in the 2024 Annual Report. Save as disclosed in this announcement, the content of the 2024 Annual Report remains unchanged.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 27 October 2025

As at the date of this announcement, the Directors are:

Executive Directors
Mr. Yan Li *(Chairman and Chief Executive Officer)*
Mr. Li Xiaoshuang

Non-executive Directors
Dr. He Yiwu
Mr. Lyu Changshang

Independent Non-executive Directors
Mr. Lee See Barry
Mr. Huang Jiang
Prof. Huang Cibo

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.